Summit Therapeutics Inc
SMMT25.000USD
-0.880-3.40%
종가 07/11, 16:00（ET）시세는 15분 지연됩니다
18.54B시가총액
손실P/E TTM
자세한 내용은 Summit Therapeutics Inc 회사
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
회사 정보
종목 코드 SMMT
회사 이름Summit Therapeutics Inc
상장일Oct 14, 2004
설립일2020
CEODr. Mahkam (Maky) Zanganeh
직원 수159
유형Ordinary Share
회계 연도 종료Oct 14
주소601 Brickell Key Drive
도시MIAMI
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호33131
전화13052032034
웹사이트https://www.smmttx.com/
종목 코드 SMMT
상장일Oct 14, 2004
설립일2020
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
데이터 없음
지역별USD
이름
수익
비율
Latin America
0.00
0.00%
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Tue, Jun 3
마지막 업데이트: Tue, Jun 3
주주
주주 유형
주주
주주
비율
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
주주
주주
비율
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
주주 유형
주주
비율
Individual Investor
84.32%
Investment Advisor
4.94%
Hedge Fund
4.18%
Investment Advisor/Hedge Fund
3.96%
Research Firm
0.39%
Bank and Trust
0.07%
Pension Fund
0.02%
Sovereign Wealth Fund
0.01%
Other
2.10%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
428
726.72M
97.85%
-882.09K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Duggan (Robert William)
555.75M
74.83%
+74.55K
+0.01%
May 30, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
Baker Bros. Advisors LP
24.42M
3.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
1.57%
-30.07K
-0.26%
Mar 31, 2025
Fidelity Management & Research Company LLC
9.31M
1.25%
+1.29M
+16.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.51M
1.01%
-43.09K
-0.57%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.46M
0.87%
-11.97K
-0.19%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
0.65%
-751.52K
-13.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.28M
0.44%
+84.03K
+2.63%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sun, Jul 6
마지막 업데이트: Sun, Jul 6
이름
비율
Tema Oncology ETF
2.79%
ProShares Ultra Nasdaq Biotechnology
1.8%
Invesco Nasdaq Biotechnology ETF
1.51%
SPDR S&P Biotech ETF
1.11%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.23%
iShares Biotechnology ETF
0.22%
더 보기
Tema Oncology ETF
비율2.79%
ProShares Ultra Nasdaq Biotechnology
비율1.8%
Invesco Nasdaq Biotechnology ETF
비율1.51%
SPDR S&P Biotech ETF
비율1.11%
Virtus LifeSci Biotech Clinical Trials ETF
비율0.99%
Invesco NASDAQ Next Gen 100 ETF
비율0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
비율0.64%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
비율0.23%
iShares Biotechnology ETF
비율0.22%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
